Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 10, 2000, Pages 467-475

  Bechtel, Y C ^a   Haffen, E ^a   Lelouet, H ^a   Brientini, M P ^a   Paintaud, G ^a   Miguet, J P ^a   Bechtel, P R ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Alcoholic cirrhosis; Caffeine; Metabolism

Indexed keywords

1 METHYLURATE; 1 METHYLXANTHINE; 1,3 DIMETHYLURATE; 1,7 DIMETHYLURATE; 3 METHYLXANTHINE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; 7 METHYLXANTHINE; CAFFEINE; DRUG METABOLITE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACETYLATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; URINARY EXCRETION;

EID: 0033791299     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38467     Document Type: Article

References (36)

1. Cost B1 conference on variability and specificity of drag metabolism. Luxembourg Office for official publications of the European Communities
2. Products of metabolism of caffeine
3. The pharmacology of caffeine
4. Guide to drug dosage in hepatic disease
5. A population and family study of N-acetyltransferase using caffeine urinary metabolites
6. Acetylation polymorphism expression in patients before and after liver transplantation: Influence of host-graft phenotypes
7. Quantitative assessment of deranged hepatic function: A missed opportunity?
8. Human arylamine N-acetyltransferase genes: Isolation, chromosal localisation and functional expression
9. Pharmacokinetics of caffeine
10. The effect of liver disease on urine caffeine metabolite ratios
11. Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases
12. Evaluation of caffeine as a test drug for CYP1A2, NAT-2 and CY P2E1 phenotyping in man by in vivo versus in vitro correlations
13. A simple test for acetylation phenotype using caffeine
14. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA expressed human CYP1A2 and CYP2E1
15. Comparison of level of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples
16. Drug metabolism in liver disease
17. Delayed gastric emptying in patients with liver cirrhosis
18. The use of caffeine for enzyme assays a critical appraisal
19. Drug acetylation in liver disease
20. The disposition of dapsone in cirrhosis
21. Clinical pharmacokinetics in patients with liver disease
22. Drug and the liver
23. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: An update
24. Effects of liver diseases on drug metabolism
25. A routine method for the establishment of permanent growing lymphoblastoid
26. Transection of oesophagus for bleeding oesophageal varices
27. Effects of liver disease on pharmacokinetics
28. Effects of liver disease on pharmacokinetics: An update
29. Caffeine metabolism in patients with chronic liver disease
30. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test
31. Caffeine urinary metabolite ratios as markers of enzyme activity: A theoretical assessment
32. Caffeine clearance and biotransformation in patients with chronic liver disease
33. The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease
34. Caffeine as a probe drug for CYP1A2 activity: Potential influence, of renal factors on urinary phenotype trait measurements
35. Disease and drug protein binding
36. Effects of hepatic disease on clinical pharmacokinetics